Incannex Healthcare Inc. (IXHL) stock
IXHLNasdaqPharmaceutical PreparationsFiscal year ends June 30
$1.74−0.19 (-9.84%)
Close on Nov 17, 2026Market cap $21.83MP/E –Yield –
Incannex Healthcare r&d expenses
Research and development expenses are spending on new products and technology.
Incannex Healthcare's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.21M, down 41.9% year over year. For fiscal 2026 it was $5.21M, down 51.5% from the year before. The highest annual figure on record is $12.88M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $5.21M | -51.5% |
| FY2025 | Jun 30, 2025 | $10.75M | -16.6% |
| FY2024 | Jun 30, 2024 | $12.88M | +104.1% |
| FY2023 | Jun 30, 2023 | $6.31M | +17.4% |
| FY2022 | Jun 30, 2022 | $5.37M | +13.1% |
| FY2021 | Jun 30, 2021 | $4.75M | +125.0% |
| FY2020 | Jun 30, 2020 | $2.11M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $1.12M | +0.3% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $1.49M | -59.8% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $321.00K | -88.3% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $2.28M | +61.2% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $1.12M | -61.3% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $3.70M | -15.1% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $2.74M | -16.5% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $1.41M | -46.4% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $2.90M | +11.0% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $4.36M | +154.6% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $3.28M | +99.9% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $2.64M | +70.3% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $2.61M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $1.71M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $1.64M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $1.55M | – |
See a number that looks wrong?